N
NeoCura
AI-powered RNA platform for developing neoantigen vaccines
About NeoCura
Founded in 2017 by Wang Yi, NeoCura is a biotechnology company leveraging artificial intelligence for the research and development of innovative RNA-based drugs. The firm operates an integrated AI platform that utilizes molecular and clinical data for in-depth drug target mining and automated drug design. This platform underpins the development of personalized neoantigen vaccines and other immunotherapies for cancer treatment.
NeoCura's business model centers on creating a pipeline of proprietary drug candidates and forming strategic collaborations to advance them through clinical trials. The company's product suite includes AI-guided neoantigen therapeutics (NeoCura Vac), cancer detection diagnostics, and AI bioinformatics services for multi-omics analysis. A key offering, NEO_PLIN2101, is a personalized mRNA neoantigen vaccine designed based on a patient's specific tumor mutations to activate a targeted anti-tumor immune response. The company has established R&D and GMP production centers in Beijing, Shenzhen, and Guangzhou to support its pipeline development and clinical demands.
The company serves the oncology market, collaborating with pharmaceutical companies and top-tier hospitals to conduct clinical trials. For instance, NeoCura has partnered with Innovent Biologics to test its neoantigen vaccine in combination with sintilimab, an immune checkpoint inhibitor. Since its inception, NeoCura has secured significant funding, including a Series A round of $38.2M in December 2020 and a Series A+ round of RMB 500 million in December 2021, from investors such as CDH Investments, PICC Capital, and IDG Capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Changping District, China
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 48.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2021 | $69M | $275M | Shunxi Private Equity Fund Management · Junying Investment · Yahui Zhou · CDH Investments | ↗ |
Growth signals
Latest recorded traffic for NeoCura is 470 monthly website visits, up 1075% over the last three months. NeoCura's team grew 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NeoCura in the Changping District ecosystem
The NeoCura office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
PICC Capital- SMShunxi Private Equity Fund Management
- JIJunying Investment
Yahui Zhou
CDH Investments
PICC Capital Investment Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeoCura on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeoCura’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








